5th World Congress on Cancer Therapy
Chamow & Associates Inc., USA
Steven Chamow, PhD., has 28 years of experience in biopharmaceutical product development. He is currently principal consultant at Chamow & Associates, Inc., working with biotechnology companies to design and implement development strategies for new therapeutic products. During his career, he served in roles of increasing responsibility at Genentech, Scios, Abgenix, Genitope and Intradigm and has contributed to the development of three marketed products (Avastin, Natrecor, Vectibix). Chamow was educated at the University of California (UC Santa Cruz, B.A. in biology; UC Davis, PhD. in biochemistry), and completed postdoctoral training at the National Institutes of Health. He is author or co-author of more than 50 scientifi c publications and patents and serves on the editorial board of the journal mAbs. Chamow recently completed his second book (Therapeutic Fc-Fusion Proteins) published by Wiley-Blackwell and released in 2014.